These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 33935636)

  • 1. Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.
    Namba MD; Leyrer-Jackson JM; Nagy EK; Olive MF; Neisewander JL
    Front Neurosci; 2021; 15():650785. PubMed ID: 33935636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of neuroimmune signaling and glutamate plasticity in addiction.
    Gipson CD; Rawls S; Scofield MD; Siemsen BM; Bondy EO; Maher EE
    J Neuroinflammation; 2021 Feb; 18(1):56. PubMed ID: 33612110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing the preclinical study of comorbid neuroHIV and substance use disorders: Current perspectives and future directions.
    Namba MD; Xie Q; Barker JM
    Brain Behav Immun; 2023 Oct; 113():453-475. PubMed ID: 37567486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stress- and drug-induced neuroimmune signaling as a therapeutic target for comorbid anxiety and substance use disorders.
    Smiley CE; Wood SK
    Pharmacol Ther; 2022 Nov; 239():108212. PubMed ID: 35580690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroimmune modulators as novel pharmacotherapies for substance use disorders.
    Grodin EN
    Brain Behav Immun Health; 2024 Mar; 36():100744. PubMed ID: 38435721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
    Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
    Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.
    Woodcock EA; Hillmer AT; Mason GF; Cosgrove KP
    Mol Neuropsychiatry; 2019 Jun; 5(3):125-146. PubMed ID: 31312635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroimmune mechanisms of psychostimulant and opioid use disorders.
    Hofford RS; Russo SJ; Kiraly DD
    Eur J Neurosci; 2019 Aug; 50(3):2562-2573. PubMed ID: 30179286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical neuroscience of addiction: similarities and differences between alcohol and other drugs.
    Karoly HC; YorkWilliams SL; Hutchison KE
    Alcohol Clin Exp Res; 2015 Nov; 39(11):2073-84. PubMed ID: 26414497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunities for the development of neuroimmune therapies in addiction.
    Ray LA; Roche DJ; Heinzerling K; Shoptaw S
    Int Rev Neurobiol; 2014; 118():381-401. PubMed ID: 25175870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimmune signaling in alcohol use disorder.
    Erickson EK; Grantham EK; Warden AS; Harris RA
    Pharmacol Biochem Behav; 2019 Feb; 177():34-60. PubMed ID: 30590091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroimmune mechanisms of alcohol and drug addiction.
    Cui C; Shurtleff D; Harris RA
    Int Rev Neurobiol; 2014; 118():1-12. PubMed ID: 25175859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of co-occurring addictions, posttraumatic stress disorder, and major depressive disorder in detoxification treatment seekers: Implications for improving detoxification treatment outcomes.
    Anderson RE; Hruska B; Boros AP; Richardson CJ; Delahanty DL
    J Subst Abuse Treat; 2018 Mar; 86():45-51. PubMed ID: 29415850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
    Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
    Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deployment of personnel to military operations: impact on mental health and social functioning.
    Bøg M; Filges T; Jørgensen AMK
    Campbell Syst Rev; 2018; 14(1):1-127. PubMed ID: 37131363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of gut-immune-brain signaling in substance use disorders.
    Lucerne KE; Kiraly DD
    Int Rev Neurobiol; 2021; 157():311-370. PubMed ID: 33648673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
    McCabe SE; West BT; Strobbe S; Boyd CJ
    J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence.
    Coller JK; Hutchinson MR
    Pharmacol Ther; 2012 May; 134(2):219-45. PubMed ID: 22316499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of N-acetylcysteine in the management of substance use disorders.
    McClure EA; Gipson CD; Malcolm RJ; Kalivas PW; Gray KM
    CNS Drugs; 2014 Feb; 28(2):95-106. PubMed ID: 24442756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis.
    Devoe DJ; Dimitropoulos G; Anderson A; Bahji A; Flanagan J; Soumbasis A; Patten SB; Lange T; Paslakis G
    J Eat Disord; 2021 Dec; 9(1):161. PubMed ID: 34895358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.